Clinical Trial Update: Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing Factor Xa inhibitor PRT054021 to enoxaparin for prevention of venous thromboembolism; study completed with results posted in 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)
• PRT054021 (PRT054021)

Snippet

Sponsor: Portola Pharmaceuticals | Conditions: Thromboembolism | Phase 2 | Status: COMPLETED | Results posted: 2017-12-15